Skip to main content
Caplight Logo









Adventris Pharmaceuticals

Adventris Pharmaceuticals

Private
Baltimore, MarylandHealthcare & Life Scienceshttps://www.adventris.com/

Last Round

Seed

Oct 18, 2024

Total Funding Raised

$12.5M

Company Overview

Adventris Pharmaceuticals is a biotechnology company that develops cancer vaccines designed to train the immune system to recognize and attack cancer-causing mutations.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

cancer vaccinetherapeutic vaccineKRAS mutationoncologybiotechnologydrug discoveryprecision medicineimmunotherapycancer immunotherapyoncogenevaccine platformbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Adventris Pharmaceuticals Comparables

Compare Adventris Pharmaceuticals with similar companies based on industry and business-model similarity.

Adventris Pharmaceuticals comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Elicio Therapeutics
81%
Circio Holding ASA
78%
Scancell Holdings Plc
70%

Adventris Pharmaceuticals Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedOct 18, 2024
Pre SeedOct 2, 2023

Adventris Pharmaceuticals Investors

Notable investors and investment history

Adventris Pharmaceuticals investors
InvestorRounds
Refactor CapitalPre Seed
Johns Hopkins Technology VenturesPre Seed
Johns Hopkins Technology VenturesPre Seed
Y CombinatorPre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 2, 2023

    $500K round with Refactor Capital and Y Combinator.

Adventris Pharmaceuticals Filings

Explore SEC and related filing metadata, where available.

Adventris Pharmaceuticals filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Adventris Pharmaceuticals's valuation, stock price, and market status.

Is Adventris Pharmaceuticals a public or private company?

Adventris Pharmaceuticals is a private company.

What is the current stock price of Adventris Pharmaceuticals?

Adventris Pharmaceuticals is a private company with no public stock price. No recent secondary market data is available.

How much is Adventris Pharmaceuticals worth (valuation)?

Valuation information for Adventris Pharmaceuticals is not publicly available.

Can I buy Adventris Pharmaceuticals stock?

Adventris Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Adventris Pharmaceuticals's last funding round?

Adventris Pharmaceuticals's most recent funding round was Seed on October 18, 2024.

Who are the main investors in Adventris Pharmaceuticals?

Key investors in Adventris Pharmaceuticals include Refactor Capital, Johns Hopkins Technology Ventures, Y Combinator.

Will Adventris Pharmaceuticals IPO soon?

No public IPO plans have been announced for Adventris Pharmaceuticals.

How can I track Adventris Pharmaceuticals secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Adventris Pharmaceuticals's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBaltimore, Maryland
Employee Range7
Year Founded2022
Last FundingOct 18, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?